SAN DIEGO, Jan. 19 /PRNewswire-FirstCall/ -- Aethlon Medical, Inc. announced today that its Chief Science Officer, Dr. Richard H. Tullis, will give a clinical presentation of the Aethlon Hemopurifier(R) at the 12th International Conference on Dialysis on January 22nd. The presentation will review treatment outcomes of dialysis patients infected with Hepatitis-C (HCV), and will discuss the additional use of the Hemopurifier(R) in HIV and Cancer care. The conference will be held at the Marriott New Orleans in New Orleans, Louisiana. Additional information, including the speaker agenda, can be accessed online at: http://www.renalresearch.com.
About Aethlon Medical
Aethlon Medical creates diagnostic and therapeutic device solutions for infectious disease and cancer. Our Hemopurifier(R) represents the first-in-class medical device to selectively adsorb viruses and immunosuppressive toxins from the bloodstream. The Hemopurifier(R) seeks to improve Hepatitis-C treatment outcomes and serves as a broad-spectrum treatment countermeasure against bioterror and pandemic threats. Additional information regarding Aethlon Medical can be accessed online at www.aethlonmedical.com.
CONTACT: CONTACT: Jon Cunningham of RedChip Companies, Inc.,
1-800-733-2447, ext. 107, Jon@redchip.com, for Aethlon Medical, Inc.; or
Jim Joyce, Chairman, CEO, +1-858-459-7800, ext. 301, jj@aethlonmedical.com,
or Jim Frakes, Senior VP Finance, +1-858-459-7800, ext. 300,
jfrakes@aethlonmedical.com, both of Aethlon Medical, Inc.
Web site: http://www.aethlonmedical.com/
http://www.renalresearch.com/
